Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma

被引：25

作者：

Kenney, Patrick A. ^{[1
]}

Wood, Christopher G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Unit 1373, Houston, TX 77030 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 02期

关键词：

Renal cell carcinoma; Adjuvant therapy; Neoadjuvant therapy; Cytoreductive nephrectomy; Immunotherapy; Targeted therapy; Angiogenesis inhibitor; Tyrosine kinase inhibitor; POSTOPERATIVE PROGNOSTIC NOMOGRAM; NEPHRON-SPARING SURGERY; CHRONIC KIDNEY-DISEASE; RADICAL NEPHRECTOMY; PHASE-III; RANDOMIZED-TRIAL; PRIMARY TUMOR; INTERFERON-ALPHA; CYTOREDUCTIVE NEPHRECTOMY; HIGH-RISK;

D O I：

10.1016/j.ucl.2012.01.005

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Proper integration of surgery and systemic therapy is essential for improving outcomes in renal cell carcinoma (RCC). There is no current role for adjuvant therapy after nephrectomy for clinically localized disease. The potential benefits of neoadjuvant therapy for locally advanced nonmetastatic disease are in need of further study. In metastatic disease, the proper integration of cytoreductive surgery and systemic therapy remains to be elucidated. Presurgical targeted therapy is feasible and may be beneficial. Pending the results of randomized controlled trials, upfront cytoreductive nephrectomy in appropriate patients will likely continue as the paradigm of choice in metastatic RCC.

引用

页码：211 / +

页数：22

共 131 条

[1] Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib [J].

Abel, E. Jason ;

Culp, Stephen H. ;

Tannir, Nizar M. ;

Tamboli, Pheroze ;

Matin, Surena F. ;

Wood, Christopher G. .

EUROPEAN UROLOGY, 2011, 60 (06) :1273-1279

[2] Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma [J].

Abel, E. Jason ;

Culp, Stephen H. ;

Tannir, Nizar M. ;

Matin, Surena F. ;

Tamboli, Pheroze ;

Jonasch, Eric ;

Wood, Christopher G. .

EUROPEAN UROLOGY, 2011, 59 (01) :10-15

[3] Neoadjuvant chemotherapy for invasive bladder cancer -: art. no. CD005246 [J].

Abol-Enein, H ;

Bassi, P ;

Boyer, M ;

Coppin, CML ;

Cortesi, E ;

Grossman, HB ;

Hall, RR ;

Horwich, A ;

Malmström, PU ;

Martinez-Piñeiro, JA ;

Sengelov, L ;

Sherif, A ;

Wallace, DMA ;

Bono, AV ;

Goebell, PJ ;

Groshen, S ;

Stöckle, FMTM ;

Studer, U ;

Clarke, NW ;

Raghavan, D ;

Roberts, JT ;

Sylvester, R ;

Parmar, MKB ;

Stewart, LA ;

Tierney, JF ;

Vale, CL .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02)

[4] Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy [J].

Amin, Chirag ;

Wallen, Eric ;

Pruthi, Raj S. ;

Calvo, Benjamin F. ;

Godley, Paul A. ;

Rathmell, W. Kimryn .

UROLOGY, 2008, 72 (04) :864-868

[5]

[Anonymous], J UROL

[6] Neoadjuvant Sunitinib Facilitates Nephron-Sparing Surgery and Avoids Long-Term Dialysis in a Patient With Metachronous Contralateral Renal Cell Carcinoma [J].

Ansari, Jawaher ;

Doherty, Alan ;

McCafferty, Ian ;

Wallace, Michael ;

Deshmukh, Nayneeta ;

Porfiri, Emilio .

CLINICAL GENITOURINARY CANCER, 2009, 7 (02) :E39-E41

[7] Is post-operative radiation for renal cell carcinoma justified? [J].

Aref, I ;

Bociek, RG ;

Salhani, D .

RADIOTHERAPY AND ONCOLOGY, 1997, 43 (02) :155-157

[8]

Arya M, 2004, NAT CLIN PRACT ONCOL, V1, P32, DOI 10.1038/ncponc0019

[9] Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J ;

Schmitt, E ;

Gertenbach, U ;

Fornara, P ;

Heynemann, H ;

Maskow, A ;

Ecke, M ;

Wöltjen, HH ;

Jentsch, H ;

Wieland, W ;

Wandert, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :843-846

[10]

BAKKE A, 1982, CANCER RES, V42, P3880

← 1 2 3 4 5 6 7 8 9 10 →